专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080286266A1 Novel Use of Il-1Beta Compounds 有权
标题翻译： II-1Beta化合物的新用途
公开(公告)号：US20080286266A1
公开(公告)日：2008-11-20
申请号：US12090490
申请日：2006-10-24
申请人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
发明人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
IPC分类号： A61K39/395 , A61P29/00
CPC分类号： C07K16/245 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
摘要翻译：本发明涉及IL-1β-配体/ IL-1受体破坏性化合物（本文称为“IL-1β化合物”）的新用途。例如破坏IL-1β配体-IL-1受体相互作用的小分子化合物，IL-1β抗体或IL-1受体抗体。本文所述的IL-1β结合分子，例如本文公开的抗体，例如 IL-1β结合化合物或IL-1受体结合化合物和/或降低IL-1β配体或IL-1受体蛋白水平的RNA化合物在治疗和/或预防自身炎症综合征中的应用。少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如，少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

2. 发明申请

US20120039910A1 Novel Use of IL-1beta Compounds 有权
标题翻译： IL-1β化合物的新用途
公开(公告)号：US20120039910A1
公开(公告)日：2012-02-16
申请号：US13283165
申请日：2011-10-27
申请人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
发明人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
IPC分类号： A61K39/395 , A61P37/02
CPC分类号： C07K16/245 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
摘要翻译：本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物（本文中称为“IL-1β化合物”）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如，少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如，少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

3. 发明授权

US08409576B2 Use of IL-1beta compounds 有权
标题翻译：使用IL-1β化合物
公开(公告)号：US08409576B2
公开(公告)日：2013-04-02
申请号：US13283165
申请日：2011-10-27
申请人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
发明人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
IPC分类号： A61K39/395 , C07K16/24 , C12P21/08
CPC分类号： C07K16/245 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
摘要翻译：本发明涉及使用IL-1和配体/ IL-1受体破坏化合物（本文中称为IL-1β化合物）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如，少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如，少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

4. 发明授权

US08105587B2 Methods of treating arthritis using IL-1β binding molecules 有权
标题翻译：使用IL-1和bgr治疗关节炎的方法结合分子
公开(公告)号：US08105587B2
公开(公告)日：2012-01-31
申请号：US12090490
申请日：2006-10-24
申请人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
发明人： Phil Lowe , Hermann Gram , Thomas Jung , Timothy Wright , Trevor Mundel
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/245 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
摘要翻译：本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物（本文中称为“IL-1β化合物”）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如，少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如，少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

5. 发明申请

US20090136965A1 Use of antibody-ligand binding to characterise diseases 审中-公开
标题翻译：使用抗体 - 配体结合来表征疾病
公开(公告)号：US20090136965A1
公开(公告)日：2009-05-28
申请号：US11914152
申请日：2006-05-08
申请人： Peter Lloyd , Phil Lowe , Steve Pascoe
发明人： Peter Lloyd , Phil Lowe , Steve Pascoe
IPC分类号： G01N33/53
CPC分类号： G01N33/6854 , G01N33/536
摘要： We have found that when an antibody binds to (captures) its specific ligand, the antibody-ligand complex is redirected to a route of elimination which is different from that which occurs naturally for the specific ligand that is not bound to an antibody. As a consequence, the amount of antibody-bound ligand in the blood increases over time. The increase in total ligand concentration is a property that is specific to the patient to whom the antibody is administered. Accordingly, the invention provides a method for diagnosing disease in a subject and a method for identifying the most appropriate treatment for a particular patient. Patients who produce more ligand, and thus more antibody-ligand complex, may be more likely to have a disease which is predominantly driven by that ligand. These patients should respond better to a therapy targeted against that ligand. The better understanding of the underlying malfunctions in disease biology provided by the methods of the invention, in respect of the rates of production of natural ligands in health and disease, provides a logical and targeted selection of the appropriate treatments to address specific biological abnormalities.
摘要翻译：我们已经发现，当抗体结合（捕获）其特异性配体时，抗体 - 配体复合物被重定向到消除途径，其不同于不与抗体结合的特异性配体天然存在的途径。因此，血液中抗体结合配体的量随时间增加。总配体浓度的增加是对施用抗体的患者特异性的特性。因此，本发明提供了用于诊断受试者疾病的方法以及用于鉴定特定患者最合适治疗的方法。产生更多配体，因此更多的抗体 - 配体复合物的患者可能更可能具有主要由该配体驱动的疾病。这些患者应该对针对该配体的治疗效果更好。通过本发明方法提供的关于疾病生物学中潜在的功能障碍的更好的理解，就天然配体在健康和疾病中的生产率而言，提供了适当的治疗方案的合乎逻辑和有针对性的选择，以解决具体的生物学异常。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式